Risk of Hepatitis B Virus (HBV) Reactivation in HBsAg-Negative, Anti-HBc-Negative Patients Receiving Rituximab for Autoimmune Diseases in HBV Endemic Areas-Reference-Cited by-同舟云学术

Risk of Hepatitis B Virus (HBV) Reactivation in HBsAg-Negative, Anti-HBc-Negative Patients Receiving Rituximab for Autoimmune Diseases in HBV Endemic Areas

Published:2022-10-21 Issue:2 Volume:17 Page:288-298
ISSN:1976-2283
Container-title:Gut and Liver
language:en
Short-container-title:Gut and Liver

Author:

Lan Ting-Yuan¹^ORCID,Lin Yen-Chun²^ORCID,Tseng Tai-Chung³⁴⁵^ORCID,Yang Hung-Chih³^ORCID,Kao Jui-Hung²^ORCID,Cheng Chiao-Feng²^ORCID,Lee Tai-Ju⁶^ORCID,Huang Shang-Chin⁷^ORCID,Lu Cheng-Hsun⁶^ORCID,Li Ko-Jen⁶^ORCID,Hsieh Song-Chou⁶^ORCID

Affiliation:

1. Division of Rheumatology, Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan

2. Department of Internal Medicine, National Taiwan University Hospital Yun-Lin Branch, Douliu, Taiwan

3. Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

4. Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan

5. Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan

6. Division of Rheumatology, Department of Internal Medicine, National Taiwan University, Taipei, Taiwan

7. Division of Gastroenterology, Department of Internal Medicine, National Taiwan University Hospital Bei-Hu Branch, Taipei, Taiwan

Publisher

The Editorial Office of Gut and Liver

Subject

Gastroenterology,Hepatology

Link

http://pdf.medrang.co.kr/GNL/2023/017/gnl-17-2-288.pdf

Reference30 articles.

1. Hepatitis B virus infection

2. American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy

3. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

4. EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies

5. Rituximab in the treatment of inflammatory myopathies: a review

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rituximab carries high risks of hepatitis B virus reactivation in hematologic and rheumatic patients with chronic or resolved hepatitis B;Journal of Gastroenterology and Hepatology;2024-08-24

2. Multiple drugs;Reactions Weekly;2024-07-20

3. To B or not to B: how the hepatitis B surveillance case definition can misdirect public health actions;Communicable Diseases Intelligence;2024-07-17

4. ÇÖZÜLMÜŞ HEPATİT B ENFEKSİYONLU VE ROMATİZMAL HASTALIĞI OLAN BİREYLERDE RİTUKSİMAB KULLANIMININ HEPATİT B REAKTİVASYONU ÜZERİNE ETKİSİ: TEK MERKEZLİ BİR ÇALIŞMA;İnönü Üniversitesi Sağlık Hizmetleri Meslek Yüksek Okulu Dergisi;2024-06-20

5. Chronic hepatitis B in rheumatic diseases: issues of screening and reactivation of infection: A review;Terapevticheskii arkhiv;2024-06-03